132 related articles for article (PubMed ID: 21928723)
1. Is botulinum toxin type a intraprostatic injections really effective in patients with urinary retention?
Jasiński M; Drewa T; Tyloch J; Wolski Z
Acta Pol Pharm; 2011; 68(5):765-8. PubMed ID: 21928723
[TBL] [Abstract][Full Text] [Related]
2. Botulinum toxin type A inhibits the growth of LNCaP human prostate cancer cells in vitro and in vivo.
Karsenty G; Rocha J; Chevalier S; Scarlata E; Andrieu C; Zouanat FZ; Rocchi P; Giusiano S; Elzayat EA; Corcos J
Prostate; 2009 Aug; 69(11):1143-50. PubMed ID: 19399787
[TBL] [Abstract][Full Text] [Related]
3. Prostate botulinum A toxin injection--an alternative treatment for benign prostatic obstruction in poor surgical candidates.
Kuo HC
Urology; 2005 Apr; 65(4):670-4. PubMed ID: 15833506
[TBL] [Abstract][Full Text] [Related]
4. Botulinum A toxin urethral injection for the treatment of lower urinary tract dysfunction.
Kuo HC
J Urol; 2003 Nov; 170(5):1908-12. PubMed ID: 14532805
[TBL] [Abstract][Full Text] [Related]
5. Mechanisms of prostate atrophy after glandular botulinum neurotoxin type a injection: an experimental study in the rat.
Silva J; Pinto R; Carvallho T; Coelho A; Avelino A; Dinis P; Cruz F
Eur Urol; 2009 Jul; 56(1):134-40. PubMed ID: 18649990
[TBL] [Abstract][Full Text] [Related]
6. Sustained beneficial effects of intraprostatic botulinum toxin type A on lower urinary tract symptoms and quality of life in men with benign prostatic hyperplasia.
Chuang YC; Chiang PH; Yoshimura N; De Miguel F; Chancellor MB
BJU Int; 2006 Nov; 98(5):1033-7; discussion 1337. PubMed ID: 16956361
[TBL] [Abstract][Full Text] [Related]
7. The use of botulinum toxin A injection for the management of external sphincter dyssynergia in neurologically normal children.
Franco I; Landau-Dyer L; Isom-Batz G; Collett T; Reda EF
J Urol; 2007 Oct; 178(4 Pt 2):1775-9; discussion 1779-80. PubMed ID: 17707430
[TBL] [Abstract][Full Text] [Related]
8. Relief by botulinum toxin of lower urinary tract symptoms owing to benign prostatic hyperplasia: early and long-term results.
Brisinda G; Cadeddu F; Vanella S; Mazzeo P; Marniga G; Maria G
Urology; 2009 Jan; 73(1):90-4. PubMed ID: 18995889
[TBL] [Abstract][Full Text] [Related]
9. Intraprostatic botulinum toxin type A injection for the treatment of benign prostatic hyperplasia: Initial experience with Dysport.
Nikoobakht M; Daneshpajooh A; Ahmadi H; Namdari F; Rezaeidanesh M; Amini S; Pourmand G
Scand J Urol Nephrol; 2010 Apr; 44(3):151-7. PubMed ID: 20201752
[TBL] [Abstract][Full Text] [Related]
10. [Effects of intraprostatic injection of botulinum toxin A (BTX-A) on benign prostate hyperplasia].
Xu YP; Yu X; Ye ZQ; Pan TJ; Wen HD; Wang T
Zhonghua Nan Ke Xue; 2010 Oct; 16(10):905-10. PubMed ID: 21243754
[TBL] [Abstract][Full Text] [Related]
11. Intraprostatic botulinum toxin type a injection in patients unfit for surgery presenting with refractory urinary retention and benign prostatic enlargement. Effect on prostate volume and micturition resumption.
Silva J; Silva C; Saraiva L; Silva A; Pinto R; Dinis P; Cruz F
Eur Urol; 2008 Jan; 53(1):153-9. PubMed ID: 17825981
[TBL] [Abstract][Full Text] [Related]
12. Botulinum toxin type A as migraine preventive treatment in patients previously failing oral prophylactic treatment due to compliance issues.
Cady R; Schreiber C
Headache; 2008 Jun; 48(6):900-13. PubMed ID: 18047501
[TBL] [Abstract][Full Text] [Related]
13. Botulinum neurotoxin A for male lower urinary tract symptoms.
Chartier-Kastler E; Mehnert U; Denys P; Giuliano F
Curr Opin Urol; 2011 Jan; 21(1):13-21. PubMed ID: 21099691
[TBL] [Abstract][Full Text] [Related]
14. Intraprostatic and bladder-neck injection of botulinum A toxin in treatment of males with bladder-neck dyssynergia: a pilot study.
Lim SK; Quek PL
Eur Urol; 2008 Mar; 53(3):620-5. PubMed ID: 17950522
[TBL] [Abstract][Full Text] [Related]
15. Is botulinum neurotoxin type A (BoNT-A) a novel therapy for lower urinary tract symptoms due to benign prostatic enlargement? A review of the literature.
Oeconomou A; Madersbacher H; Kiss G; Berger TJ; Melekos M; Rehder P
Eur Urol; 2008 Oct; 54(4):765-75. PubMed ID: 18571306
[TBL] [Abstract][Full Text] [Related]
16. Single-institution experience in 110 patients with botulinum toxin A injection into bladder or urethra.
Smith CP; Nishiguchi J; O'Leary M; Yoshimura N; Chancellor MB
Urology; 2005 Jan; 65(1):37-41. PubMed ID: 15667859
[TBL] [Abstract][Full Text] [Related]
17. Experience with 100 cases treated with botulinum-A toxin injections in the detrusor muscle for idiopathic overactive bladder syndrome refractory to anticholinergics.
Schmid DM; Sauermann P; Werner M; Schuessler B; Blick N; Muentener M; Strebel RT; Perucchini D; Scheiner D; Schaer G; John H; Reitz A; Hauri D; Schurch B
J Urol; 2006 Jul; 176(1):177-85. PubMed ID: 16753396
[TBL] [Abstract][Full Text] [Related]
18. Comparing two types of botulinum-A toxin detrusor injections in patients with severe neurogenic detrusor overactivity: a case-control study.
Grosse J; Kramer G; Jakse G
BJU Int; 2009 Sep; 104(5):651-6. PubMed ID: 19281462
[TBL] [Abstract][Full Text] [Related]
19. Injection of botulinum toxin type A in the urethral sphincter to treat lower urinary tract dysfunction: review of indications, techniques and results: 2011 update.
Mahfouz W; Karsenty G; Corcos J
Can J Urol; 2011 Aug; 18(4):5787-95. PubMed ID: 21854710
[TBL] [Abstract][Full Text] [Related]
20. Reduction of salivary flow with botulinum toxin: extended report on 33 patients with drooling, salivary fistulas, and sialadenitis.
Ellies M; Gottstein U; Rohrbach-Volland S; Arglebe C; Laskawi R
Laryngoscope; 2004 Oct; 114(10):1856-60. PubMed ID: 15454785
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
